摘要
目的探讨美罗培南和头孢哌酮钠舒巴坦治疗老年肺部感染患者的临床效果。方法选取2017年10月至2019年2月于我院进行治疗的54例老年肺部感染患者作为观察组,采用美罗培南进行治疗;选择同期于我院进行治疗的另外54例老年肺部感染患者作为对照组,采用头孢哌酮钠舒巴坦进行治疗。比较两组患者的治疗效果。结果观察组的细菌清除率、治疗总有效率、不良反应发生率均优于对照组(P<0.05)。结论应用美罗培南治疗老年肺部感染患者的效果优于头孢哌酮钠舒巴坦,能够更好的提升细菌清除率和治疗有效率,并减少不良反应对患者的影响。
Objective To explore the clinical effects of meropenem and cefoperazone sodium and sulbactam in the treatment of elderly patients with lung infection.Methods A total of 54 elderly patients with lung infection who were treated in our hospital from October 2017 to February 2019 were selected as the observation group and treated with meropenem,another 54 elderly patients with lung infection who were treated in our hospital during the same period were selected as the observation group.The control group was treated with cefoperazone sodium and sulbactam.The treatment effect of the two groups of patients was compared.Results The bacterial clearance rate,total effective rate of treatment,and incidence of adverse reactions in the observation group were better than those in the control group(P<0.05).Conclusion The clinical effect of meropenem in the treatment of elderly patients with pulmonary infection is better than that of cefoperazone sodium and sulbactam,which can better improve the bacterial clearance rate and therapeutic efficiency of patients,and reduce the impact of adverse reactions on patients.
作者
尚丹
SHANG Dan(Anshan Central Hospital of Liaoning Province,Anshan 114000,China)
出处
《中国医药指南》
2021年第14期30-31,共2页
Guide of China Medicine
关键词
肺部感染
老年
美罗培南
头孢哌酮钠舒巴坦
Pulmonary infection
Elderly
Meropenem
Cefoperazone sodium and sulbactam
